Trials / Completed
CompletedNCT02439203
Efficacy and Safety of JM-010 in PD With Levodopa-Induced Dyskinesia
A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Study in Subjects With Parkinson's Disease With Moderate to Severe Levodopa-induced Dyskinesia, to Assess the Efficacy, Safety/Tolerability and Pharmacokinetics of JM-010
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Bukwang Pharmaceutical · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of a randomized, double-blind, placebo-controlled, 2-way crossover study is to evaluate the efficacy, safety/tolerability and pharmacokinetics of JM-010 for the treatment of subjects with Parkinson's Disease (PD) with levodopa-induced dyskinesia (LID).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JM-010 | |
| DRUG | Placebo |
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2015-12-01
- Completion
- 2016-01-01
- First posted
- 2015-05-08
- Last updated
- 2016-01-13
Locations
1 site across 1 country: South Africa
Source: ClinicalTrials.gov record NCT02439203. Inclusion in this directory is not an endorsement.